$ 7.17
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD);...
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is undervalued on EV/EBITDA.
Target Price
The average target price of CAPR is 20 and suggests 177% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
